In advanced disease elevated levels of S100B also demonstrate a strong correlation with reduced survival as patients with stage III or IV disease and low S100B have shown statistically significant survival advantage compared to patients with elevated tumour marker [1,15]. Here, S100B is linked to neoplasm.